Abiopharma

Immediate Report about change of identifying details

Register of shareholders, changes and share capital status – final redemption of commercial papers (CP 2) and expiration of warrants

Shareholders register, changes and share capital status – exercise of warrants (Series 4) into shares

Change in corporation details

Organon & Co. - European Commission (EC) Approves Henlius andOrganon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe

European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe

Lithia & Driveway (LAD) Reports First Quarter Results

Alibaba Group Will Announce March Quarter 2026 and Full Fiscal Year 2026 Results on May 13, 2026

VEON and Kyivstar Fulfill Commitment to Invest USD 1 Billion in Ukraine over 2023-2027 Ahead of Schedule

Kyivstar and VEON Fulfill Commitment to Invest $1 Billion Investment Program in Ukraine, Exceeding Target by 30%